Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: J Urol. 2023 Jan 17;209(5):971–980. doi: 10.1097/JU.0000000000003183

Table 1.

Study population

Characteristic Participants (n=424)
Mean age, years (SD) 49 (17)
Female 199 (47%)
Race
  White 358 (84%)
  Black 32 (8%)
  Asian 17 (4%)
  Other 16 (4%)
Hispanic/Latinx ethnicity 25 (6%)
Mean body mass index, kg/m2 (SD) 30 (8)
Medical history
 Depression 115 (27%)
 Anxiety 127 (30%)
 Mood disorder (other) 15 (4%)
 Chronic pain condition 158 (37%)
Prior ureteroscopy 154 (36%)
Prior ureteral stent placement 170 (40%)
Severe pain with prior ureteral stent 80 (19%)
Severe urinary symptoms with prior ureteral stent 102 (24%)
Medication use in 30 days prior to URS
 Opioids 111 (26%)
 NSAIDs 155 (37%)
   Tamsulosin (or alpha blocker) 136 (32%)
   Oxybutynin (or anticholinergic) 9 (2.1%)

Data shown are n (%) except where indicated. SD = standard deviation; NSAIDs = nonsteroidal anti-inflammatory drugs.